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Paolo Corradini (e-mail: paolo.corradini@unimi.it)Chimeric antigen receptor (CAR) T-cell therapy as a treatment This remarkable efﬁcacy of CD19-directed CAR T-cells in
modality has accelerated in a remarkable fashion in recent years
and is now a standard of care for treating patients with relapsed
and refractory diffuse large B-cell lymphoma (DLBCL) and
relapsed pediatric and adolescent B-cell acute lymphoblastic
leukemia (B-ALL). This dramatic progress in the CAR T-cell
ﬁeld has been summarized in recent publications in Hema-
Sphere.1–8 These articles have comprehensively reviewed the
substantial successes of CAR T-cell treatment as well as the
potential for the future, but have also highlighted toxicity and
future challenges.
The success of CAR T-cell therapy has not only been due to
technological advances allowing for the manufacture of these
cells; treatment with CAR T-cells has been effective in
populations of patients where other treatments have been
unsuccessful. In DLBCL, patients with refractory disease who
have a very poor prognosis were the initial cohort to be treated
with CAR T-cells. In a prior analysis of 861 patients treated with
standard chemotherapy, the objective response rate to the next
line of standard therapy was only 26% with a complete response
(CR) rate of 7%.9 The median survival for patients was only 6.3
months with only 20% of patients still alive at 2 years. It was in
this very poor prognosis group of patients that CAR T-cell
therapy showed very high and durable responses. Similarly,
pediatric and adolescent patients with relapsed or refractory ALL
have a very poor outcome. In a review of 313 patients, CR rates
for patients in second or subsequent relapse were only 40% and
the disease-free survival for patients in CR2 and CR3 was only
27% and 15%, respectively.10 It was these challenging
subpopulations of ALL patients who received CAR T-cells and
in whom substantial and durable responses were seen.Funding/support: None.
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1DLBCL is well highlighted in a review article by Hopﬁnger et al.2
Overall, response rates in the order of 50% to 80% were seen in
patients with relapsed and refractory DLBCL and durable CRs
have persisted in approximately 40% of patients treated. A
further encouraging aspect of CAR T-cell therapy is that it has
resulted in durable CRs in patients with relapsed double and
triple hit lymphomas. These promising results have resulted in the
approval of tisagenlecleucel and axicabtagene ciloleucel for the
treatment of patients with this disease. The promising results in
relapsed and refractory patients have led to randomized trials
comparing CAR T-cell therapy to stem cell transplantation in
DLBCL patients in ﬁrst relapse. Similar outstanding results have
been seen in pediatric and adolescent patients with B-ALL as
summarized in a review article by DiNoﬁa and Maude.3 CD19-
directed CAR T-cell therapy has resulted in an approximately
50% to 60% relapse-free survival at 1 year based on multiple
clinical trials done at various institutions. These results in B-ALL
are notably better than those expected with typical salvage
chemotherapy. Tisagenlecleucel has therefore received approval
based on these encouraging results.1
The substantial progress has not been without some
challenges. Toxicities from CAR T-cell therapy are well
described in the review articles by Yáñez San Segundo et al
and Borrega et al.4,5 Based on the effects of depleting B-cells as
well as the activation of T-cells by the chimeric receptor,
multiple toxicities including cytokine release syndrome (CRS)
and neurotoxicity have complicated administration of these
products. While this was originally a signiﬁcant challenge,
comprehensive guidance has now been provided on how to
manage these complications. Careful monitoring and early
intervention has made a substantial difference to the incidence
and severity of these problems. While management of these
issues is much improved, as pointed out by Borrega et al in their
review,5 more needs to be done to better understand the
mechanism of these toxicities and deﬁne the population of
patients in whom they are more likely to develop. With more
patients treated in real life practice outside of clinical studies,
prolonged cytopenias and infections are an emerging clinical
problem requiring attention. As we move forward in this ﬁeld,
management and prevention of side effects and complications
will need to be an important area of focus.
While it may have felt in recent months that CAR T-cell
therapy has been in the fast lane as regards its development, the
road ahead may be somewhat less conducive to speedy progress.
As comprehensively reviewed by Holzinger et al,6 new designs of
CAR T-cells are being explored. This includes T cells redirected
Editorial Editorialfor universal cytokine-mediated killing (TRUCKs), bispeciﬁc
CAR T-cells, conditional CARs, and armored CAR T-cells.
Future perspectives include not only improving the CAR T-cell
product or giving CAR T-cell products in combination with
other agents,7 but also developing CAR T-cells with efﬁcacy
against myeloid and T-cell malignancies as well as solid tumors.8
Furthermore, it will also be important to protect the CAR
T-cells from immune suppression as they enter the tumor
microenvironment. Development of new cellular products and in
particular “off the shelf” CAR T-cells is likely to take time and it
may take a while before these therapies are available for routine
clinical use.
Overall, there is substantial enthusiasm for the use of CAR T-
cells to treat various hematological malignancies and solid
tumors. Phenomenal progress has been made to date in providing
this effective therapy for use in patients. As one looks to the
future, not only will it be important to optimize the current CAR
T-cell approaches but it will be important to develop the next
generation of CAR T-cells. It will also be critically important to
develop strategies for ﬁnancial compensation for these treat-
ments. All told, the future for CAR T-cells is very bright and the
hope is that we can continue to speed ahead andmake progress in
T-cell treatment of patients with malignancies.2References
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